MCID: GST040
MIFTS: 65

Gastric Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastric Adenocarcinoma

MalaCards integrated aliases for Gastric Adenocarcinoma:

Name: Gastric Adenocarcinoma 12 15 73
Adenocarcinoma of Stomach 12 6
Stomach Adenocarcinoma 12
Adenocarcinoma Gastric 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3717
NCIt 50 C4004
UMLS 73 C0278701

Summaries for Gastric Adenocarcinoma

Disease Ontology : 12 A stomach carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Gastric Adenocarcinoma, also known as adenocarcinoma of stomach, is related to gastric papillary adenocarcinoma and adenocarcinoma, and has symptoms including dyspepsia An important gene associated with Gastric Adenocarcinoma is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Iron and Irinotecan have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Stomach cancer, also known as gastric cancer, is a cancer which develops from the lining of the stomach.... more...

Related Diseases for Gastric Adenocarcinoma

Diseases related to Gastric Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 352)
# Related Disease Score Top Affiliating Genes
1 gastric papillary adenocarcinoma 32.5 ERBB2 TP53
2 adenocarcinoma 31.9 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
3 gastric cancer 31.1 AKT1 CTNNB1 ERBB2 FGFR2 H19 HOTAIR
4 squamous cell carcinoma 30.8 AKT1 BRAF CTNNB1 ERBB2 FGFR2 H19
5 peutz-jeghers syndrome 30.6 CTNNB1 PTEN SMAD4 TP53
6 familial adenomatous polyposis 30.5 CTNNB1 KRAS SMAD4 TP53
7 gastrointestinal stromal tumor 30.5 AKT1 BRAF HOTAIR KIT KRAS PTEN
8 adenoma 30.4 BRAF CTNNB1 GNAS KRAS SMAD4 TP53
9 leukemia 30.3 HOTAIR KIT NRAS RAF1 TP53
10 glioma 30.3 BRAF ERBB2 FGFR1 H19 HOTAIR PIK3CA
11 esophageal cancer 30.2 AKT1 CTNNB1 ERBB2 H19 HOTAIR HRAS
12 cowden disease 30.2 AKT1 PIK3CA PTEN SMAD4
13 small cell carcinoma 30.1 KIT PTEN TP53
14 intrahepatic cholangiocarcinoma 30.1 CTNNB1 FGFR2 KRAS TP53
15 small cell cancer of the lung 30.1 AKT1 HOTAIR KIT PIK3CA PTEN TP53
16 ovary adenocarcinoma 30.1 ERBB2 HRAS KRAS PIK3CA TP53
17 lynch syndrome 30.0 BRAF CTNNB1 KRAS TP53
18 breast adenocarcinoma 30.0 AKT1 ERBB2 H19 KRAS PIK3CA PTEN
19 cholangiocarcinoma 30.0 AKT1 BRAF CTNNB1 ERBB2 H19 KRAS
20 lipomatosis 30.0 FGFR1 PIK3CA PTEN
21 colorectal adenocarcinoma 29.9 BRAF CTNNB1 HRAS KRAS TP53
22 myeloid leukemia 29.9 HRAS KIT NRAS TP53
23 testicular germ cell tumor 29.9 BRAF HRAS KIT PTEN TP53
24 lung cancer 29.6 AKT1 BRAF ERBB2 FGFR1 FGFR2 H19
25 myeloma, multiple 29.5 AKT1 BRAF H19 HOTAIR HRAS KIT
26 hepatocellular carcinoma 29.4 AKT1 CTNNB1 FGFR1 GNAS H19 HOTAIR
27 gastric adenocarcinoma and proximal polyposis of the stomach 12.2
28 gastric cancer, hereditary diffuse 11.3
29 krukenberg carcinoma 11.2
30 gastric tubular adenocarcinoma 11.1
31 gastric cardia adenocarcinoma 11.1
32 mucinous stomach adenocarcinoma 11.1
33 gastric diffuse adenocarcinoma 11.1
34 gastric signet ring cell adenocarcinoma 11.1
35 bladder disease 10.5 AKT1 ERBB2 TP53
36 ductal carcinoma in situ 10.5 AKT1 ERBB2 TP53
37 gonadal disease 10.5 AKT1 ERBB2 TP53
38 breast ductal carcinoma 10.5 CTNNB1 ERBB2 TP53
39 cervix disease 10.5 AKT1 CTNNB1 TP53
40 sporadic breast cancer 10.5 ERBB2 PTEN TP53
41 nasopharyngeal disease 10.5 AKT1 CTNNB1 TP53
42 supratentorial cancer 10.5 AKT1 PTEN TP53
43 bent bone dysplasia syndrome 10.5 ERBB2 FGFR2
44 nervous system cancer 10.5 AKT1 PTEN TP53
45 central nervous system cancer 10.5 AKT1 PTEN TP53
46 cerebrum cancer 10.5 AKT1 PTEN TP53
47 pharynx squamous cell carcinoma 10.5 AKT1 PTEN
48 atypical teratoid rhabdoid tumor 10.5 CTNNB1 HOTAIR TP53
49 malignant spiradenoma 10.5 PIK3CA TP53
50 prostate transitional cell carcinoma 10.5 CTNNB1 PIK3CA

Graphical network of the top 20 diseases related to Gastric Adenocarcinoma:



Diseases related to Gastric Adenocarcinoma

Symptoms & Phenotypes for Gastric Adenocarcinoma

UMLS symptoms related to Gastric Adenocarcinoma:


dyspepsia

GenomeRNAi Phenotypes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 59)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.16 BRAF HRAS KRAS PIK3CA
2 Decreased viability GR00106-A-0 11.16 KRAS
3 Decreased viability GR00221-A-1 11.16 HRAS KRAS PIK3CA AKT1 FGFR1 RAF1
4 Decreased viability GR00221-A-2 11.16 HRAS KRAS PIK3CA AKT1 FGFR1 RAF1
5 Decreased viability GR00221-A-3 11.16 HRAS AKT1 NRAS
6 Decreased viability GR00221-A-4 11.16 BRAF PIK3CA AKT1
7 Decreased viability GR00231-A 11.16 RAF1
8 Decreased viability GR00301-A 11.16 BRAF KRAS RAF1 FGFR2 KIT
9 Decreased viability GR00342-S-1 11.16 FGFR2
10 Decreased viability GR00342-S-2 11.16 FGFR2
11 Decreased viability GR00342-S-3 11.16 FGFR2
12 Decreased viability GR00381-A-1 11.16 BRAF KRAS
13 Decreased viability GR00402-S-2 11.16 BRAF HRAS KRAS PIK3CA AKT1 FGFR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.29 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.29 SMAD4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.29 SMAD4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.29 PTEN
18 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.29 KIT PTEN
19 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.29 KIT PIK3CA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.29 AKT1 PIK3CA PTEN
21 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.29 PIK3CA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.29 PTEN
23 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.29 KIT
24 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.29 AKT1 PIK3CA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.29 PIK3CA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.29 SMAD4
27 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.29 SMAD4
28 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.29 PTEN
29 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.29 SMAD4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.29 KIT
31 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.29 AKT1 KIT PIK3CA PTEN SMAD4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.29 SMAD4
33 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.29 SMAD4
34 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.29 PIK3CA
35 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.29 AKT1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.29 SMAD4
37 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.29 PTEN
38 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.29 AKT1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.29 SMAD4
40 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.29 SMAD4
41 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.29 AKT1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.29 SMAD4
43 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.29 AKT1 KIT
44 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.29 KIT
45 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.29 PTEN
46 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.29 KIT
47 Decreased viability in esophageal squamous lineage GR00235-A 10.11 BRAF CTNNB1 ERBB2 GNAS HRAS KIT
48 Decreased cell migration GR00055-A-1 10.05 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K2
49 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.97 CTNNB1 ERBB2 FGFR2 HRAS NRAS PTEN
50 Decreased substrate adherent cell growth GR00193-A-1 9.91 KIT

MGI Mouse Phenotypes related to Gastric Adenocarcinoma:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.56 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
2 cardiovascular system MP:0005385 10.56 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
3 cellular MP:0005384 10.53 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
4 endocrine/exocrine gland MP:0005379 10.53 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
5 growth/size/body region MP:0005378 10.52 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
6 homeostasis/metabolism MP:0005376 10.5 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
7 integument MP:0010771 10.48 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
8 craniofacial MP:0005382 10.46 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
9 embryo MP:0005380 10.45 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
10 mortality/aging MP:0010768 10.44 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
11 digestive/alimentary MP:0005381 10.42 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 HRAS
12 immune system MP:0005387 10.4 AKT1 BRAF CTNNB1 FGFR1 FGFR2 GNAS
13 hematopoietic system MP:0005397 10.39 AKT1 BRAF CTNNB1 FGFR1 FGFR2 GNAS
14 neoplasm MP:0002006 10.38 AKT1 BRAF CTNNB1 ERBB2 FGFR2 GNAS
15 muscle MP:0005369 10.34 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
16 nervous system MP:0003631 10.33 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
17 limbs/digits/tail MP:0005371 10.31 BRAF CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
18 normal MP:0002873 10.31 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
19 liver/biliary system MP:0005370 10.3 AKT1 BRAF CTNNB1 FGFR2 GNAS KIT
20 hearing/vestibular/ear MP:0005377 10.28 BRAF CTNNB1 FGFR1 FGFR2 GNAS KIT
21 adipose tissue MP:0005375 10.24 AKT1 BRAF FGFR2 GNAS MAP2K2 PIK3CA
22 no phenotypic analysis MP:0003012 10.17 CTNNB1 FGFR1 FGFR2 GNAS HRAS KIT
23 renal/urinary system MP:0005367 10.06 BRAF CTNNB1 FGFR1 FGFR2 GNAS HRAS
24 reproductive system MP:0005389 10.03 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
25 pigmentation MP:0001186 9.97 BRAF CTNNB1 FGFR2 KIT KRAS NRAS
26 respiratory system MP:0005388 9.93 AKT1 BRAF CTNNB1 ERBB2 FGFR2 GNAS
27 skeleton MP:0005390 9.89 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
28 vision/eye MP:0005391 9.4 BRAF CTNNB1 FGFR1 FGFR2 KIT KRAS

Drugs & Therapeutics for Gastric Adenocarcinoma

Drugs for Gastric Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4 7439-89-6 23925
2
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
3
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 6006 143
4
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
5
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
6
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68538-85-2
7
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
8
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 180288-69-1 9903
9
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
10
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 59-30-3 6037
12
Camptothecin Experimental Phase 4,Phase 2,Phase 1 7689-03-4
13 Ferric Compounds Phase 4
14 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
17 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
18 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
19 Antidotes Phase 4,Phase 3,Phase 2,Phase 1
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Vitamin B9 Phase 4,Phase 3,Phase 1,Phase 2
23 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
24 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
25 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1
26 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
27 Topoisomerase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
28 Folate Phase 4,Phase 3,Phase 1,Phase 2
29 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
31 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
32 Anti-Ulcer Agents Phase 4,Phase 3,Phase 1
33 Antacids Phase 4,Phase 3,Phase 1
34 Proton Pump Inhibitors Phase 4
35 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
36 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
37
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
38
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
39
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
40
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
41
Epirubicin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 56420-45-2 41867
42
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
43
Pancrelipase Approved, Investigational Phase 3,Phase 2,Phase 1 53608-75-6
44
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
45
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
46
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
47
Floxuridine Approved Phase 3,Phase 2 50-91-9 5790
48
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
49
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
50
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616

Interventional clinical trials:

(show top 50) (show all 391)
# Name Status NCT ID Phase Drugs
1 Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Unknown status NCT02426034 Phase 4 Apatinib
2 Iron Replacement in Oesophagogastric Neoplasia Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
3 Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection Completed NCT00844675 Phase 4 rabeprazole;placebo
4 Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection Completed NCT02401477 Phase 4 Ilaprazole + Amoxicillin
5 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
6 Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma Terminated NCT00871273 Phase 4 capecitabine
7 A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer Terminated NCT01260194 Phase 4 trastuzumab [Herceptin]
8 Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Unknown status NCT01015339 Phase 3 Paclitaxel;capecitabine;capecitabine;cisplatin
9 Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction Unknown status NCT01468389 Phase 3 Capecitabine;capecitabine
10 SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer Unknown status NCT01583361 Phase 3 Oxaliplatin+S-1;Adjuvant Oxaliplatin/S-1(SOX)
11 Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer Unknown status NCT01283217 Phase 3 DS;SP
12 Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma Unknown status NCT01711242 Phase 3 Capecitabine;Oxaliplatin
13 Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction Unknown status NCT01962246 Phase 2, Phase 3 Oxaliplatin; Capecitabine
14 Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer Unknown status NCT02537171 Phase 3 apatinib
15 Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer Unknown status NCT00450203 Phase 2, Phase 3 capecitabine;cisplatin;Epirubicin;Lapatinib
16 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
17 Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Completed NCT01640782 Phase 3 Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
18 S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients Completed NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
19 A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma Completed NCT01170663 Phase 3 Placebo;Paclitaxel
20 Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma Completed NCT00323830 Phase 3 Capecitabine, cisplatin, Radiotherapy (+/-)
21 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed NCT00678535 Phase 3 Cetuximab;Capecitabine;Cisplatin
22 Covered Versus Uncovered Self-expandable Metallic Stents for Malignant Gastric Outlet Obstruction Completed NCT01646476 Phase 3
23 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3 docetaxel;steroid therapy
24 Trial of Adjuvant Chemotherapy for Gastric Cancer Completed NCT00296335 Phase 3 Mitomycin, doxifluridine and cisplatin;Mitomycin and doxifluridine
25 A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer Completed NCT02560974 Phase 3 Capecitabine;Oxaliplatin
26 Trial of Adjuvant Chemotherapy for Gastric Cancer Completed NCT00296322 Phase 3 cisplatin, mitomycin-C, doxifluridine
27 Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer Completed NCT00411229 Phase 3 Capecitabine;Oxaliplatin
28 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed NCT00917384 Phase 3 Placebo
29 Metastatic Gastric Cancer FFCD 03-07 Completed NCT00374036 Phase 3 ECC;FOLFIRI
30 S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer Completed NCT00182611 Phase 3 cisplatin;tegafur-gimeracil-oteracil potassium
31 A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer Completed NCT01662869 Phase 3 5-Fluoruracil;Folinic acid;Onartuzumab;Oxaliplatin;Placebo
32 Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma Completed NCT01491698 Phase 3
33 Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer Completed NCT00002615 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil
34 Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer Completed NCT00020787 Phase 3 cisplatin;fluorouracil
35 Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) Completed NCT00879333 Phase 3 Everolimus;Everolimus placebo;Best Supportive Care (BSC)
36 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Completed NCT00052910 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
37 Capecitabine or Observation for Patients With pT1N+M0 or pT2-3N0M0 Gastric Adenocarcinoma Undergoing R0 Resection Recruiting NCT03817268 Phase 3 Capecitabine monotherapy
38 Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Recruiting NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
39 D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma Recruiting NCT01882933 Phase 3 HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin
40 Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection Recruiting NCT01534546 Phase 3 Oxaliplatin capecitabine;Oxaliplatin S-1;Oxaliplatin S-1
41 Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer Recruiting NCT01815853 Phase 3 Neoadjuvant Chemotherapy;Adjuvant Chemotherapy
42 Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Recruiting NCT02578368 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Trastuzumab;sodium folinate
43 Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer Recruiting NCT02240524 Phase 3
44 Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer Recruiting NCT02512380 Phase 3 Docetaxel;oxaliplatin;s1;oxaliplatin;s1
45 A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer Recruiting NCT02144727 Phase 3
46 Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial Recruiting NCT01761461 Phase 3 TS-1, oxaliplatin
47 Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer Recruiting NCT02289547 Phase 3 Capecitabine
48 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Recruiting NCT02898077 Phase 3 Ramucirumab;Paclitaxel;Placebo
49 Preoperative Stomach Cancer Induction Chemotherapy and Radiation Therapy Recruiting NCT03223740 Phase 3
50 Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05) Recruiting NCT01917552 Phase 3 capecitabine

Search NIH Clinical Center for Gastric Adenocarcinoma

Genetic Tests for Gastric Adenocarcinoma

Anatomical Context for Gastric Adenocarcinoma

MalaCards organs/tissues related to Gastric Adenocarcinoma:

41
Lymph Node, Liver, Lung, Bone, Skin, Eye, Colon

Publications for Gastric Adenocarcinoma

Articles related to Gastric Adenocarcinoma:

(show top 50) (show all 1521)
# Title Authors Year
1
B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies. ( 30546950 )
2019
2
CTNNBIP1 downregulation is associated with tumor grade and viral infections in gastric adenocarcinoma. ( 30076728 )
2019
3
Collision tumor consisting of a colorectal adenocarcinoma and dissemination of a gastric adenocarcinoma. ( 29326826 )
2018
4
Vimentin-positive gastric adenocarcinoma arising in a hyperplastic polyp. ( 29417386 )
2018
5
<i>Helicobacter pylori</i> eradication treatment and the risk of gastric adenocarcinoma in a Western population. ( 29382776 )
2018
6
Combination of arginine, glutamine, and omega-3 fatty acid supplements for perioperative enteral nutrition in surgical patients with gastric adenocarcinoma or gastrointestinal stromal tumor (GIST): A prospective, randomized, double-blind study. ( 29848836 )
2018
7
A Six-Gene Signature Predicts Clinical Outcome of Gastric Adenocarcinoma. ( 29848271 )
2018
8
Gastric adenocarcinoma expressing human epidermal growth factor receptor in South Asian population. ( 29806596 )
2018
9
Effects of carvacrol on human fibroblast (WS-1) and gastric adenocarcinoma (AGS) cells in vitro and on Wistar rats in vivo. ( 29442269 )
2018
10
Subhyaloid hemorrhage as the first presenting sign of gastric adenocarcinoma. ( 29310953 )
2018
11
Reduced Expression of Deubiquitinase USP33 Is Associated with Tumor Progression and Poor Prognosis of Gastric Adenocarcinoma. ( 29802710 )
2018
12
Tumor of the Turkish saddle with endocrine disorders as the first manifestation of gastric adenocarcinoma. ( 29385110 )
2018
13
Geographic variation in molecular subtype for gastric adenocarcinoma. ( 29960981 )
2018
14
Effect of total number of harvested lymph nodes on survival outcomes after curative resection for gastric adenocarcinoma: findings from an eastern high-volume gastric cancer center. ( 29329569 )
2018
15
Orally administered brown seaweed-derived I^-glucan effectively restrained development of gastric dysplasia in A4gnt KO mice that spontaneously develop gastric adenocarcinoma. ( 29763881 )
2018
16
<i>Celastrus orbiculatus</i> extracts induce apoptosis and inhibit invasion by targeting the maspin gene in human gastric adenocarcinoma cells. ( 29387218 )
2018
17
PD-1 and PD-L1 Up-regulation Promotes T-cell Apoptosis in Gastric Adenocarcinoma. ( 29599324 )
2018
18
Sequential spinal and intracranial dural metastases in gastric adenocarcinoma: A case report. ( 29434454 )
2018
19
Quercetin Suppresses CYR61-Mediated Multidrug Resistance in Human Gastric Adenocarcinoma AGS Cells. ( 29364834 )
2018
20
2,4-Di-tert-butylphenol, a potential HDAC6 inhibitor, induces senescence and mitotic catastrophe in human gastric adenocarcinoma AGS cells. ( 29427610 )
2018
21
Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India ( 29802704 )
2018
22
Neoplastic Lesions of Gastric Adenocarcinoma and Proximal Polyposis Syndrome (GAPPS) Are Gastric Phenotype. ( 29112017 )
2018
23
Martrilin-3 (MATN3) Overexpression in Gastric Adenocarcinoma and its Prognostic Significance. ( 29343680 )
2018
24
Effects of miR-21 on proliferation and apoptosis in human gastric adenocarcinoma cells. ( 29403555 )
2018
25
Expression and prognostic value of cell-cycle-associated genes in gastric adenocarcinoma. ( 29884122 )
2018
26
Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. ( 29954358 )
2018
27
Potentially curable gastric adenocarcinoma treated without surgery. ( 29859338 )
2018
28
l-asparaginase induces intrinsic mitochondrial-mediated apoptosis in human gastric adenocarcinoma cells and impedes tumor progression. ( 29966654 )
2018
29
First report of an Asian family with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) revealed with the germline mutation of the APC exon 1B promoter region. ( 29968043 )
2018
30
GalNAc-T15 in gastric adenocarcinoma: Characterization according to tissue architecture and cellular location. ( 29943957 )
2018
31
Next-generation sequencing analysis for gastric adenocarcinoma with enteroblastic differentiation: emphasis on the relationship with hepatoid adenocarcinoma. ( 29751042 )
2018
32
CURRENT STATUS OF THE MULTIDISCIPLINARY TREATMENT OF GASTRIC ADENOCARCINOMA. ( 29972401 )
2018
33
Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. ( 29866946 )
2018
34
A Rare Case of an Advanced Gastric Adenocarcinoma in a Teenage Syrian Boy. ( 30538876 )
2018
35
Influence of thermal ablation of hepatic metastases from gastric adenocarcinoma on long-term survival: Systematic review and pooled analysis. ( 30544454 )
2018
36
Gastric adenocarcinoma is concurrent with metastatic neuroendocrine cancer treated with nivolumab and chemotherapy: A case report. ( 30546888 )
2018
37
TP53 inactivation and expression of methylation-associated proteins in gastric adenocarcinoma with enteroblastic differentiation. ( 30554333 )
2018
38
GSK-3 inhibitors enhance TRAIL-mediated apoptosis in human gastric adenocarcinoma cells. ( 30557366 )
2018
39
Use of peritoneal washing cytology for the detection of free peritoneal cancer cells before and after surgical treatment of gastric adenocarcinoma. ( 30488834 )
2018
40
MMP7 Induces T-DM1 Resistance and Leads to The Poor Prognosis of Gastric Adenocarcinoma via a DKK1-Dependent Manner. ( 30501604 )
2018
41
Characterization of PI3KCA and BRAF mutations in gastric adenocarcinoma: An approach to a personalized targeted therapy for Moroccan HER2 overexpressed patients. ( 30503528 )
2018
42
Gastric Adenocarcinoma Predictive Long Intergenic Non-Coding RNA Promotes Tumor Occurrence and Progression in Non-Small Cell Lung Cancer via Regulation of the miR-661/eEF2K Signaling Pathway. ( 30522114 )
2018
43
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). ( 30529902 )
2018
44
A Case of Complete Remission from Advanced Gastric Adenocarcinoma with Synchronous Liver Metastasis in Response to EOX Chemotherapy. ( 30425863 )
2018
45
The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study. ( 30426294 )
2018
46
Proposal and validation of a modified staging system to improve the prognosis predictive performance of the 8th AJCC/UICC pTNM staging system for gastric adenocarcinoma: a multicenter study with external validation. ( 30454049 )
2018
47
PTPRF as a novel tumor suppressor through deactivation of ERK1/2 signaling in gastric adenocarcinoma. ( 30464527 )
2018
48
Compensatory gastric stretching following subtotal gastric resection due to gastric adenocarcinoma in a diamond python (Morelia spilota spilota). ( 30478847 )
2018
49
ASO Author Reflections: Survival Impacts of Therapy and Complications in Gastric Adenocarcinoma. ( 30374929 )
2018
50
Are the indications for postoperative radiotherapy in the NCCN guidelines for patients with gastric adenocarcinoma too broad? A study based on the SEER database. ( 30390644 )
2018

Variations for Gastric Adenocarcinoma

ClinVar genetic disease variations for Gastric Adenocarcinoma:

6 (show top 50) (show all 725)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
3 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh37 Chromosome 19, 4117551: 4117551
4 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh38 Chromosome 19, 4117553: 4117553
5 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
6 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh38 Chromosome 18, 51065548: 51065548
7 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
8 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh38 Chromosome 18, 51067036: 51067036
9 CDH1 NM_004360.4(CDH1): c.1018A> G (p.Thr340Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs116093741 GRCh37 Chromosome 16, 68846047: 68846047
10 CDH1 NM_004360.4(CDH1): c.1018A> G (p.Thr340Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs116093741 GRCh38 Chromosome 16, 68812144: 68812144
11 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
12 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
13 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
14 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
15 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
16 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
17 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
18 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
19 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
20 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
21 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
22 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
23 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
24 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
25 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
26 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
27 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
28 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
29 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
30 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
31 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
32 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
33 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
34 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh38 Chromosome 10, 121520163: 121520163
35 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
36 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
37 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
38 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
39 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
40 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
41 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
42 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
43 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh38 Chromosome 11, 533467: 533467
44 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
45 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
46 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
47 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
48 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh38 Chromosome 11, 533466: 533466
49 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
50 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289

Cosmic variations for Gastric Adenocarcinoma:

9 (show top 50) (show all 52)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6982918 YES1 skin,eye,carcinoma,NS c.851G>A p.G284E 18:743289-743289 3
2 COSM4736805 TSC1 skin,eye,carcinoma,NS c.2065C>T p.R689C 9:132903794-132903794 3
3 COSM6971614 TRAF7 skin,eye,carcinoma,NS c.349G>A p.E117K 16:2171264-2171264 3
4 COSM45444 TP53 skin,eye,carcinoma,NS c.587G>T p.R196L 17:7674944-7674944 3
5 COSM44126 TP53 skin,eye,carcinoma,NS c.507G>A p.M169I 17:7675105-7675105 3
6 COSM6937552 TP53 skin,eye,carcinoma,NS c.859G>C p.E287Q 17:7673761-7673761 3
7 COSM10724 TP53 skin,eye,carcinoma,NS c.839G>C p.R280T 17:7673781-7673781 3
8 COSM43583 TP53 skin,eye,carcinoma,NS c.425C>T p.P142L 17:7675187-7675187 3
9 COSM4462891 STK40 skin,eye,carcinoma,NS c.1265C>T p.S422F 1:36341798-36341798 3
10 COSM4462893 STK40 skin,eye,carcinoma,NS c.1265C>T p.S422F 1:36341798-36341798 3
11 COSM6009093 SPEN skin,eye,carcinoma,NS c.9563C>T p.P3188L 1:15935803-15935803 3
12 COSM6982915 SOX2 skin,eye,carcinoma,NS c.237G>A p.W79* 3:181712597-181712597 3
13 COSM5538304 RNF43 skin,eye,carcinoma,NS c.866C>T p.S289F 17:58360235-58360235 3
14 COSM5468163 RAD52 skin,eye,carcinoma,NS c.779G>A p.R260Q 12:916430-916430 3
15 COSM144245 PTCH1 skin,eye,carcinoma,NS c.1585A>T p.K529* 9:95476776-95476776 3
16 COSM221754 PPP6C skin,eye,carcinoma,NS c.790C>T p.R264C 9:125149801-125149801 3
17 COSM6971613 PIK3R1 skin,eye,carcinoma,NS c.608A>G p.Y203C 5:68279707-68279707 3
18 COSM6971611 NOTCH2 skin,eye,carcinoma,NS c.4091C>T p.P1364L 1:119925725-119925725 3
19 COSM6072631 KDM5A skin,eye,carcinoma,NS c.973C>T p.P325S 12:354132-354132 3
20 COSM6982913 INPP4A skin,eye,carcinoma,NS c.407G>A p.G136E 2:98536148-98536148 3
21 COSM6982909 IKBKE skin,eye,carcinoma,NS c.537C>A p.Y179* 1:206476359-206476359 3
22 COSM498 HRAS skin,eye,carcinoma,NS c.182A>T p.Q61L 11:533874-533874 3
23 COSM732369 FBXW7 skin,eye,carcinoma,NS c.535C>T p.R179C 4:152350091-152350091 3
24 COSM6971612 CTNNB1 skin,eye,carcinoma,NS c.1420C>T p.R474* 3:41233763-41233763 3
25 COSM13828 CDKN2A skin,eye,carcinoma,NS c.149A>G p.Q50R 9:21974679-21974679 3
26 COSM4900080 BTK skin,eye,carcinoma,NS c.262G>A p.E88K 23:101371680-101371680 3
27 COSM6971615 BRIP1 skin,eye,carcinoma,NS c.1463C>T p.P488L 17:61793607-61793607 3
28 COSM6971610 BARD1 skin,eye,carcinoma,NS c.722C>T p.S241F 2:214781152-214781152 3
29 COSM6982919 AR skin,eye,carcinoma,NS c.1883G>A p.G628E 23:67686124-67686124 3
30 COSM1432255 APC skin,eye,carcinoma,NS c.3367C>T p.Q1123* 5:112838961-112838961 3
31 COSM6971616 skin,eye,carcinoma,NS c.1463C>T p.P488L 17:61793607-61793607 3
32 COSM6985419 skin,eye,carcinoma,NS c.149A>G p.Q50R 9:21974679-21974679 3
33 COSM3733332 skin,eye,carcinoma,NS c.839G>C p.R280T 17:7673781-7673781 3
34 COSM6982911 skin,eye,carcinoma,NS c.407G>A p.G136E 2:98536148-98536148 3
35 COSM6982912 skin,eye,carcinoma,NS c.407G>A p.G136E 2:98536148-98536148 3
36 COSM6985418 skin,eye,carcinoma,NS c.149A>G p.Q50R 9:21974679-21974679 3
37 COSM254987 skin,eye,carcinoma,NS c.839G>C p.R280T 17:7673781-7673781 3
38 COSM6982921 skin,eye,carcinoma,NS c.1313G>A p.G438E 23:67686124-67686124 3
39 COSM6971609 skin,eye,carcinoma,NS c.722C>T p.S241F 2:214781152-214781152 3
40 COSM6937551 skin,eye,carcinoma,NS c.859G>C p.E287Q 17:7673761-7673761 3
41 COSM6937553 skin,eye,carcinoma,NS c.859G>C p.E287Q 17:7673761-7673761 3
42 COSM1151204 skin,eye,carcinoma,NS c.901C>T p.R301C 9:125149801-125149801 3
43 COSM1649340 skin,eye,carcinoma,NS c.839G>C p.R280T 17:7673781-7673781 3
44 COSM4462892 skin,eye,carcinoma,NS c.1280C>T p.S427F 1:36341798-36341798 3
45 COSM732370 skin,eye,carcinoma,NS c.535C>T p.R179C 4:152350091-152350091 3
46 COSM1149858 skin,eye,carcinoma,NS c.181C>T p.R61C 4:152350091-152350091 3
47 COSM732371 skin,eye,carcinoma,NS c.295C>T p.R99C 4:152350091-152350091 3
48 COSM6072630 skin,eye,carcinoma,NS c.973C>T p.P325S 12:354132-354132 3
49 COSM6982920 skin,eye,carcinoma,NS c.287G>A p.G96E 23:67686124-67686124 3
50 COSM6937554 skin,eye,carcinoma,NS c.859G>C p.E287Q 17:7673761-7673761 3

Copy number variations for Gastric Adenocarcinoma from CNVD:

7 (show all 39)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14963 1 111600000 115900000 Gain C1orf88 Gastric adenocarcinoma
2 14964 1 111600000 115900000 Gain CHIA Gastric adenocarcinoma
3 14966 1 111600000 115900000 Gain OVGP1 Gastric adenocarcinoma
4 33992 1 51300000 56200000 Loss LRP8 Gastric adenocarcinoma
5 38160 10 1 3000000 Gain DIP2C Gastric adenocarcinoma
6 48224 10 99400000 102000000 Gain CHUK Gastric adenocarcinoma
7 48225 10 99400000 102000000 Gain CWF19L1 Gastric adenocarcinoma
8 48226 10 99400000 102000000 Gain SPFH1 Gastric adenocarcinoma
9 48323 11 1 21600000 Gain ST5 Gastric adenocarcinoma
10 66124 12 25358179 25403863 Amplification KRAS Gastric adenocarcinoma
11 80193 13 86500000 88800000 Loss SLITRK5 Gastric adenocarcinoma
12 81497 14 103000000 106368585 Loss IGHV3-22 Gastric adenocarcinoma
13 92520 15 41400000 42700000 Loss CAPN3 Gastric adenocarcinoma
14 92521 15 41400000 42700000 Loss GANC Gastric adenocarcinoma
15 93577 15 55800000 57100000 Gain LDHAL6B Gastric adenocarcinoma
16 93578 15 55800000 57100000 Gain MYO1E Gastric adenocarcinoma
17 97919 16 14700000 16700000 Gain PKD1P3 Gastric adenocarcinoma
18 112023 17 3773917 3814485 Loss ATP2A3 Gastric adenocarcinoma
19 112078 17 37844392 37884914 Amplification Gastric adenocarcinoma
20 112310 17 3854487 3993002 Loss ZZEF1 Gastric adenocarcinoma
21 130603 19 50000000 53800000 Gain Gastric adenocarcinoma
22 135991 12 128122223 128954165 Gain TMEM132D Gastric adenocarcinoma
23 159208 21 41400000 46944323 Loss HSF2BP Gastric adenocarcinoma
24 159209 21 41400000 46944323 Loss KIAA0179 Gastric adenocarcinoma
25 166094 3 1 3500000 Loss CNTN6 Gastric adenocarcinoma
26 169827 3 14700000 23800000 Loss UBE2E1 Gastric adenocarcinoma
27 182313 4 139500000 141700000 Loss MAML3 Gastric adenocarcinoma
28 184256 4 172200000 176600000 Loss Gastric adenocarcinoma
29 195591 5 152100000 155600000 Loss TIMD4 Gastric adenocarcinoma
30 201331 5 68400000 73300000 Gain FCHO2 Gastric adenocarcinoma
31 221297 7 142800000 147500000 Loss CNTNAP2 Gastric adenocarcinoma
32 233707 8 12700000 19100000 Gain Gastric adenocarcinoma
33 236938 8 19100000 23400000 Loss INTS10 Gastric adenocarcinoma
34 237477 8 23400000 27400000 Loss CDCA2 Gastric adenocarcinoma
35 237478 8 23400000 27400000 Loss DOCK5 Gastric adenocarcinoma
36 237479 8 23400000 27400000 Loss GNRH1 Gastric adenocarcinoma
37 237480 8 23400000 27400000 Loss KCTD9 Gastric adenocarcinoma
38 237883 8 27400000 29700000 Loss EXTL3 Gastric adenocarcinoma
39 262032 X 29400000 31500000 Gain XK Gastric adenocarcinoma

Expression for Gastric Adenocarcinoma

Search GEO for disease gene expression data for Gastric Adenocarcinoma.

Pathways for Gastric Adenocarcinoma

Pathways related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 241)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.42 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
2
Show member pathways
14.28 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
3
Show member pathways
14.13 AKT1 BRAF ERBB2 FGFR1 FGFR2 GNAS
4
Show member pathways
14.1 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
5
Show member pathways
13.99 AKT1 BRAF ERBB2 FGFR1 FGFR2 GNAS
6
Show member pathways
13.98 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
7
Show member pathways
13.95 AKT1 BRAF ERBB2 FGFR1 FGFR2 GNAS
8
Show member pathways
13.82 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
9
Show member pathways
13.79 AKT1 BRAF ERBB2 FGFR1 FGFR2 GNAS
10
Show member pathways
13.77 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
11
Show member pathways
13.74 AKT1 ERBB2 FGFR1 FGFR2 HRAS KIT
12
Show member pathways
13.71 AKT1 FGFR1 GNAS HRAS KRAS NRAS
13
Show member pathways
13.69 AKT1 ERBB2 FGFR1 FGFR2 GNAS HRAS
14
Show member pathways
13.68 AKT1 BRAF CTNNB1 GNAS HRAS KRAS
15
Show member pathways
13.64 AKT1 BRAF ERBB2 FGFR1 FGFR2 HRAS
16
Show member pathways
13.62 AKT1 ERBB2 FGFR1 FGFR2 GNAS HRAS
17
Show member pathways
13.59 AKT1 CTNNB1 ERBB2 FGFR1 FGFR2 HRAS
18
Show member pathways
13.56 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
19
Show member pathways
13.52 AKT1 GNAS HRAS KRAS NRAS PIK3CA
20
Show member pathways
13.51 AKT1 BRAF ERBB2 GNAS HRAS KRAS
21
Show member pathways
13.36 AKT1 ERBB2 FGFR1 FGFR2 KIT PIK3CA
22
Show member pathways
13.36 AKT1 FGFR1 FGFR2 GNAS HRAS KIT
23
Show member pathways
13.36 AKT1 BRAF FGFR1 FGFR2 GNAS HRAS
24
Show member pathways
13.35 AKT1 CTNNB1 GNAS HRAS KRAS MAP2K2
25
Show member pathways
13.32 AKT1 BRAF CTNNB1 GNAS HRAS KRAS
26
Show member pathways
13.32 AKT1 BRAF CTNNB1 GNAS HRAS KRAS
27
Show member pathways
13.31 AKT1 CTNNB1 ERBB2 FGFR1 FGFR2 GNAS
28
Show member pathways
13.29 AKT1 GNAS HRAS KRAS MAP2K2 NRAS
29 13.27 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
30
Show member pathways
13.26 AKT1 CTNNB1 HRAS KRAS MAP2K2 NRAS
31
Show member pathways
13.26 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
32
Show member pathways
13.23 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K2
33
Show member pathways
13.22 AKT1 BRAF ERBB2 HRAS KRAS MAP2K2
34
Show member pathways
13.22 AKT1 BRAF GNAS HRAS KIT KRAS
35
Show member pathways
13.21 ERBB2 FGFR1 FGFR2 GNAS HRAS KIT
36
Show member pathways
13.21 AKT1 BRAF CTNNB1 ERBB2 HRAS KRAS
37
Show member pathways
13.17 AKT1 BRAF GNAS HRAS KRAS NRAS
38
Show member pathways
13.17 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
39
Show member pathways
13.15 AKT1 HRAS KRAS MAP2K2 NRAS RAF1
40
Show member pathways
13.12 AKT1 BRAF CTNNB1 GNAS HRAS KRAS
41
Show member pathways
13.11 AKT1 HRAS KRAS MAP2K2 NRAS PIK3CA
42
Show member pathways
13.11 AKT1 BRAF ERBB2 FGFR1 FGFR2 GNAS
43
Show member pathways
13.11 AKT1 BRAF ERBB2 FGFR1 FGFR2 GNAS
44
Show member pathways
13.08 BRAF HRAS KRAS MAP2K2 NRAS PIK3CA
45
Show member pathways
13.08 AKT1 BRAF HRAS KRAS MAP2K2 PIK3CA
46 13.08 AKT1 BRAF ERBB2 FGFR1 FGFR2 HRAS
47
Show member pathways
13.05 FGFR1 FGFR2 HRAS KRAS NRAS PIK3CA
48
Show member pathways
13.05 AKT1 ERBB2 FGFR1 FGFR2 HRAS KIT
49
Show member pathways
13.04 AKT1 BRAF GNAS HRAS KRAS MAP2K2
50
Show member pathways
13 AKT1 BRAF CTNNB1 FGFR1 FGFR2 GNAS

GO Terms for Gastric Adenocarcinoma

Cellular components related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.8 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
2 receptor complex GO:0043235 9.67 ERBB2 FGFR1 FGFR2 KIT
3 cell-cell junction GO:0005911 9.56 AKT1 CTNNB1 KIT MAP2K2
4 cytoplasm GO:0005737 9.53 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
5 cytoplasmic side of plasma membrane GO:0009898 9.5 KIT MAP2K2 PTEN
6 cytosol GO:0005829 10 AKT1 BRAF CTNNB1 ERBB2 FGFR1 GNAS

Biological processes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.99 BRAF CTNNB1 FGFR1 KIT SMAD4
2 negative regulation of neuron apoptotic process GO:0043524 9.97 BRAF HRAS KRAS PIK3CA
3 protein autophosphorylation GO:0046777 9.97 AKT1 ERBB2 FGFR1 FGFR2 KIT
4 positive regulation of protein kinase B signaling GO:0051897 9.97 ERBB2 FGFR1 FGFR2 KIT PIK3CA
5 peptidyl-tyrosine phosphorylation GO:0018108 9.95 BRAF ERBB2 FGFR1 FGFR2 KIT MAP2K2
6 negative regulation of signal transduction GO:0009968 9.94 ERBB2 FGFR1 FGFR2 KIT
7 positive regulation of DNA-binding transcription factor activity GO:0051091 9.94 AKT1 CTNNB1 KIT PTEN
8 phosphatidylinositol phosphorylation GO:0046854 9.92 ERBB2 FGFR1 FGFR2 KIT PIK3CA
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.91 AKT1 BRAF PIK3CA RAF1
10 Ras protein signal transduction GO:0007265 9.9 HRAS KRAS NRAS TP53
11 positive regulation of epithelial cell proliferation GO:0050679 9.89 ERBB2 FGFR2 HRAS
12 cellular response to growth factor stimulus GO:0071363 9.88 AKT1 CTNNB1 ERBB2
13 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.88 HRAS KRAS NRAS RAF1
14 positive regulation of MAPK cascade GO:0043410 9.88 CTNNB1 ERBB2 FGFR1 FGFR2 HRAS KIT
15 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.87 FGFR1 FGFR2 PIK3CA
16 visual learning GO:0008542 9.87 BRAF KIT KRAS
17 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.87 BRAF ERBB2 FGFR1 FGFR2 HRAS KIT
18 thymus development GO:0048538 9.86 BRAF CTNNB1 RAF1
19 cell proliferation GO:0008283 9.86 AKT1 CTNNB1 ERBB2 HRAS PTEN RAF1
20 regulation of cell differentiation GO:0045595 9.85 CTNNB1 FGFR1 RAF1
21 protein kinase B signaling GO:0043491 9.85 AKT1 PIK3CA PTEN
22 somatic stem cell population maintenance GO:0035019 9.85 BRAF KIT RAF1 SMAD4
23 positive regulation of MAP kinase activity GO:0043406 9.85 ERBB2 FGFR1 HRAS KIT KRAS
24 cellular response to nerve growth factor stimulus GO:1990090 9.84 AKT1 BRAF PTEN
25 midbrain development GO:0030901 9.84 CTNNB1 FGFR1 FGFR2
26 phosphatidylinositol 3-kinase signaling GO:0014065 9.82 AKT1 ERBB2 PIK3CA
27 positive regulation of gene expression GO:0010628 9.81 AKT1 BRAF CTNNB1 ERBB2 HRAS KIT
28 positive regulation of mesenchymal cell proliferation GO:0002053 9.8 CTNNB1 FGFR1 FGFR2
29 branching involved in salivary gland morphogenesis GO:0060445 9.73 FGFR1 FGFR2
30 morphogenesis of embryonic epithelium GO:0016331 9.73 CTNNB1 FGFR2
31 anoikis GO:0043276 9.73 AKT1 PIK3CA
32 positive regulation of phospholipase C activity GO:0010863 9.73 FGFR1 HRAS KIT
33 mesenchymal cell differentiation GO:0048762 9.72 FGFR1 FGFR2
34 negative regulation of cell size GO:0045792 9.72 AKT1 PTEN
35 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.72 MAP2K2 TP53
36 positive regulation of phospholipase activity GO:0010518 9.72 FGFR1 FGFR2
37 regulation of axon regeneration GO:0048679 9.71 BRAF PTEN
38 response to isolation stress GO:0035900 9.71 HRAS KRAS
39 lung-associated mesenchyme development GO:0060484 9.71 CTNNB1 FGFR1 FGFR2
40 myeloid progenitor cell differentiation GO:0002318 9.7 BRAF KIT
41 hair follicle placode formation GO:0060789 9.69 CTNNB1 GNAS
42 cellular response to decreased oxygen levels GO:0036294 9.68 AKT1 PTEN
43 orbitofrontal cortex development GO:0021769 9.68 FGFR1 FGFR2
44 mesenchymal cell proliferation involved in lung development GO:0060916 9.66 CTNNB1 FGFR2
45 ventricular zone neuroblast division GO:0021847 9.65 FGFR1 FGFR2
46 negative regulation of apoptotic process GO:0043066 9.65 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
47 fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development GO:0035607 9.62 FGFR1 FGFR2
48 MAPK cascade GO:0000165 9.32 BRAF ERBB2 FGFR1 FGFR2 HRAS KIT
49 signal transduction GO:0007165 10.33 AKT1 BRAF ERBB2 GNAS HRAS KIT
50 positive regulation of transcription by RNA polymerase II GO:0045944 10.25 AKT1 CTNNB1 FGFR2 HRAS RAF1 SMAD4

Molecular functions related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 protein serine/threonine kinase activity GO:0004674 9.97 AKT1 BRAF MAP2K2 PIK3CA RAF1
2 protein heterodimerization activity GO:0046982 9.97 BRAF CTNNB1 ERBB2 RAF1 SMAD4 TP53
3 enzyme binding GO:0019899 9.95 AKT1 CTNNB1 PTEN RAF1 TP53
4 protein kinase activity GO:0004672 9.92 AKT1 BRAF ERBB2 FGFR1 FGFR2 KIT
5 transmembrane signaling receptor activity GO:0004888 9.88 ERBB2 FGFR1 FGFR2 KIT
6 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.78 ERBB2 FGFR1 FGFR2 KIT
7 protein phosphatase binding GO:0019903 9.77 CTNNB1 ERBB2 TP53
8 RNA polymerase II transcription factor binding GO:0001085 9.73 CTNNB1 SMAD4 TP53
9 protein tyrosine kinase activity GO:0004713 9.73 BRAF ERBB2 FGFR1 FGFR2 KIT MAP2K2
10 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.71 ERBB2 FGFR1 FGFR2 KIT
11 1-phosphatidylinositol-3-kinase activity GO:0016303 9.7 FGFR1 FGFR2 PIK3CA
12 kinase activity GO:0016301 9.61 AKT1 BRAF ERBB2 FGFR1 FGFR2 KIT
13 I-SMAD binding GO:0070411 9.58 CTNNB1 SMAD4
14 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.55 ERBB2 FGFR1 FGFR2 KIT PIK3CA
15 fibroblast growth factor-activated receptor activity GO:0005007 9.54 FGFR1 FGFR2
16 nucleotide binding GO:0000166 9.36 AKT1 BRAF ERBB2 FGFR1 FGFR2 HRAS
17 protein binding GO:0005515 10.41 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR2
18 transferase activity GO:0016740 10.16 AKT1 BRAF ERBB2 FGFR1 FGFR2 KIT
19 ATP binding GO:0005524 10.07 AKT1 BRAF ERBB2 FGFR1 FGFR2 KIT
20 identical protein binding GO:0042802 10.03 AKT1 BRAF ERBB2 FGFR1 PTEN RAF1

Sources for Gastric Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37